TECH OUTLOOK 6DECEMBER 2023EditorialStacey Smith Editor-in-Chiefeditor@pharmatechoutlook.comThe pharmaceutical industry is undergoing a transformative phase, marked by an accelerated adoption of emerging technologies and methodologies. Among the most noteworthy are single-use bioreactors, 3D-printed pharmaceuticals, and digital twins. These shifts, however, are not occurring in a vacuum; they are spurred by changing market dynamics, such as the growing need for small-batch production to meet the demands of precision medicine.One of the most striking advancements is the rising prominence of single-use bioreactors. These devices offer a streamlined approach to drug development and manufacturing by eliminating some of the more cumbersome and time-consuming steps inherent in traditional systems. For instance, single-use bioreactors remove the need for intricate cleaning and validation procedures between different stages of production. This not only results in substantial cost savings but also boosts operational efficiency by cutting downtime. Digital twins represent another paradigm shift. These virtual replicas of physical systems allow organizations to simulate many scenarios in a risk-free environment. The objective is preemptively identifying potential bottlenecks or errors and refining the process for optimal performance. Because of these promising trends, the global pharmaceutical manufacturing market is steadily growing at a CAGR of 7.63 percent by 2030. This edition of Pharma Tech Outlook brings insights into the latest developments in the pharma manufacturing space and how organizations leverage these trends to structure more effective therapeutics with fewer side effects. It features a thought leadership article from Oliver Vogt, VP of manufacturing operations, multi-site, Emergent BioSolutions, who sheds light on the need for improved efficiency and cost-effectiveness that drives the industry's increasing adoption of isolator technology for drug product manufacturing. It also features an article from Safwan Kezbor, senior medical director, clinical development at Shionogi, who highlights three most recent advancements that have substantial potential in the future of rare disease drug development: precision medicine, gene therapy, and AI. We also bring you the story of the top pharma manufacturing companies leveraging cutting-edge technologies to improve patient health. One of them is Magnattack Global, which upholds the highest food safety and quality standards with its innovative Mag-Ram magnetic separator. We also share stories of innovative companies like De Dietrich Process Systems, Dec Group, and Tempris.In this edition featuring the Top Pharma Manufacturing Solutions Providers 2023, we hope you find the right partner to meet your organization's needs.Unlocking Innovations to Reshape Pharma ManufacturingCopyright © 2023 ValleyMedia, Inc. All rights reserved. Reproduction in whole or part of any text, photography or illustrations without written permission from the publisher is prohibited. The publisher assumes no responsibility for unsolicited manuscripts, photographs or illustrations. Views and opinions expressed in this publication are not necessarily those of the magazine and accordingly, no liability is assumed by the publisher thereof.DECEMBER - 9 - 2023, Vol 09 - Issue 26 (ISSN 2644-2787) Published by ValleyMedia, Inc. To subscribe to Pharma Tech OutlookVisit www.pharmatechoutlook.com Disclaimer: *Some of the Insights are based on our interviews with CIOs and CXOsEditor-in-ChiefStacey SmithVisualizerRonald DonovanEditorial StaffAaron Pierce Ava GarciaJenna VegasCarolynn Walters Justin SmithPaul Barbersales@pharmatechoutlook.comeditor@pharmatechoutlook.commarketing@pharmatechoutlook.comEmail:Edwin PaulTECH OUTLOOKTECH OUTLOOK
< Page 5 | Page 7 >